Skip to main content
. 2018 May 3;39(7):948–954. doi: 10.1093/carcin/bgy060

Table 3.

Urinary levels of 8-epi-prostaglandin F (8-epiPGF) in relation to lung cancer risk in total and subgroups by smoking status, The Shanghai Cohort Study 1986–2013

8-epiPGF in quartile (pg/mg Cr)a Cases Controls OR (95% CI)b
All subjects
 First quartileb 93 150 1.00
 Second quartile 139 151 1.31 (0.88, 1.94)
 Third quartile 147 156 1.18 (0.80, 1.74)
 Fourth quartile 231 153 1.79 (1.22, 2.63)
P for trend 0.007
Never smokers
 First quartile (<172) 23 29 1.00
 Second quartile (172–241) 32 27 1.62 (0.70, 3.78)
 Third quartile (242–338) 37 30 1.54 (0.68, 3.52)
 Fourth quartile (>338) 24 30 0.71 (0.29, 1.75)
P for trend 0.528
Former smokers
 First quartile (<165) 11 15 1.00
 Second quartile (165–210) 7 14 1.04 (0.19, 5.75)
 Third quartile (211–267) 8 15 0.83 (0.21, 3.34)
 Fourth quartile (>267) 32 14 5.25 (0.94, 29.41)
P for trend 0.035
Current smokers
 First quartile (<340) 59 106 1.00
 Second quartile (340–487) 100 110 1.33 (0.83, 2.12)
 Third quartile (488–650) 102 111 1.13 (0.70, 1.82)
 Fourth quartile (>650) 175 109 1.99 (1.26, 3.14)
P for trend 0.007

aQuartile cut-off values were based on the distribution of urinary 8-epiPGF among control subjects stratified by smoking status.

bOdds ratios (95% confidence intervals) were derived from conditional logistic regression models with adjustment for level of education, body mass index (kg/m2), smoking status, number of cigarettes/day, years of smoking and years since quitting smoking (for former smokers only).